T: +44 20 3709 5700
hyloris@consilium-comms.com
About Hyloris Pharmaceuticals SA
Based in Liège, Belgium, Hyloris is an innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system. Hyloris currently has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, commercialised through its partner AltaThera, and Maxigesic® IV, a non-opioid analgesic product for the treatment of pain, developed with the Company s partner, AFT Pharmaceuticals. Additionally, Hyloris has 12 product candidates in various stages of development across the Company s wider portfolio with a focus on intravenous cardiovascular dru
Global Deep Learning in Medical Image Processing Market to 2030 with IBM, GE Healthcare and Google Entering into Strategic Alliances with Big Pharma Players
News provided by
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Deep Learning Market: Focus on Medical Image Processing, 2020-2030 report features an extensive study on the current market landscape offering an informed opinion on the likely adoption of such solutions over the next decade. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
One of the key objectives of this report was to estimate the existing market size and the future growth potential within the deep learning market (medical image processing segment), such as global radiology spending across countries, number of radiologists employed across different regions of globe, annual salary of radiologists, rate of adoption of deep learning-based solutions, we have d